Journal
Alzheimer's & Dementia: Translational Research & Clinical Interventions
Publication Date
1-1-2025
Volume
11
Issue
1
First Page
e70033
Document Type
Open Access Publication
DOI
10.1002/trc2.70033
Rights and Permissions
Hartz SM, Schindler SE, Streitz ML, et al. Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer's disease. Alzheimer's Dement. 2025;11:e70033. https://doi.org/10.1002/trc2.70033 © 2025 The Author(s). Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Recommended Citation
Hartz, Sarah M; Schindler, Suzanne E; Streitz, Marissa L; Moulder, Krista L; Mozersky, Jessica; Wang, Guoqiao; Xiong, Chengjie; and Morris, John C, "Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer's disease." Alzheimer's & Dementia: Translational Research & Clinical Interventions. 11, 1. e70033 (2025).
https://digitalcommons.wustl.edu/oa_4/6967
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
